Ongoing

4

200

Europe

ECULIZUMAB, Ultomiris, Concentrate for solution for infusion, Soliris 300, ULTOMIRIS

Roche Farma S. A. U. que realiza el ensayo en España y que actua como representante F.Hoffmann-La Roche Ltd, F. Hoffman-La Roche Ltd., Chugai Pharmaceutical Co. Ltd

Paroxysmal nocturnal hemoglobinuria (PNH) that is treated with either eculizumab or ravulizumab as per local label Hemoglobinuria paroxística nocturna (HPN) que se trata con eculizumab o ravulizumab según la etiqueta local, PNH is a rare, acquired life-threatening disease, characterized by presence of impaired red blood cells that are easily destroyed, leading to hemoglobin in the urine and anemia as main manifestations HPN es enfermedad rara, adqui q pone en peligro la vida, por la presencia de glóbu rojos deteriorados q se destruyen fácil, lo q lleva a la hemoglobina en orina y anemia como manifestaciones ppales, Diseases [C] - Blood and lymphatic diseases [C15]

 

 

Not yet recruiting

4

20

Europe

ULTOMIRIS, ALXN1210, Concentrate for solution for infusion, ULTOMIRIS

Alexion Pharmaceuticals Inc., Alexion Pharmaceuticals, Inc.

Paroxysmal nocturnal hemoglobinuria (PNH), Paroxysmal nocturnal hemoglobinuria (PNH), Diseases [C] - Blood and lymphatic diseases [C15]

 

 

Completed

3

139

Europe, Canada, US, RoW

Ravulizumab OBDS, Ravulizumab, ALXN1210

Alexion Pharmaceuticals, Inc.

Paroxysmal Nocturnal Hemoglobinuria

02/21

08/23

Completed

3

11

Europe, Japan, US

Eculizumab

Alexion Pharmaceuticals, Inc.

Myasthenia Gravis, Myasthenia Gravis, Juvenile Form, Myasthenia Gravis, Generalized

01/22

11/23

Active, not recruiting

3

40

Europe

Spacing of Eculizumab infusions

University Hospital, Tours, Centre Hospitalier Universitaire, Amiens, University Hospital, Angers, Centre Hospitalier Universitaire de Besancon, University Hospital, Caen, Centre Hospitalier of Chartres, Nantes University Hospital, University of Nancy, Poitiers University Hospital, Rennes University Hospital, University Hospital, Rouen, University Hospital, Strasbourg, France, Centre Hospitalier Universitaire de Nice, Hôpital Necker-Enfants Malades, Tenon Hospital, Paris, University Hospital, Lille, Reims University Hospital, University Hospital, Clermont-Ferrand, Assistance Publique Hopitaux De Marseille, Hospices Civils de Lyon

Hemolytic-Uremic Syndrome, Atypical

12/23

06/24

Active, not recruiting

3

204

Europe, Japan, RoW

Crovalimab, Eculizumab

Hoffmann-La Roche, Chugai Pharmaceutical

Paroxysmal Nocturnal Hemoglobinuria

11/22

06/28

Active, not recruiting

3

64

US

Imlifidase, IdeS, HMED-IdeS, PLEX, Plasma exchange, PE, IVIg, Intravenous immunoglobulin, Anti-CD20 antibodies, Rituximab, Eculizumab, Soliris, Remain on wait list

Hansa Biopharma AB

Kidney Transplantation in Highly Sensitized Patients

06/25

06/25

Not yet recruiting

3

10

Europe

Eculizumab administration

University Hospital, Rouen

Thrombotic Microangiopathies

09/25

09/25

Recruiting

3

66

Europe

Soliris®, Eculizumab, Renin angiotensin system blockers

Assistance Publique - Hôpitaux de Paris

Hypertensive Emergency-associated Hemolytic Uremic Syndrome

05/26

11/27

Active, not recruiting

3

190

Europe, Canada, Japan, US, RoW

Crovalimab, Eculizumab

Hoffmann-La Roche, Chugai Pharmaceutical

Paroxysmal Nocturnal Hemoglobinuria

09/29

09/29

Terminated

2/3

5

Europe, Canada, Japan, US, RoW

Eculizumab, Soliris

Alexion Pharmaceuticals, Inc.

Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder

07/23

07/23

Active, not recruiting

2

15

 

Alexion Pharmaceuticals Australasia Pty Ltd, Alexion Pharmaceuticals Australasia Pty Ltd

Atypical Hemolytic-Uremic Syndrome

 

 

Not yet recruiting

2

50

Europe

Solaris, Infusion, Solaris

Newcastle Upon Tyne Hospitals NHS Foundation Trust, National Institute for Health Research

Atypical Haemolytic Uraemic Syndrome (aHUS), aHUS is a rare disease caused by a fault in the complement system. The complement system is part of your body’s immune response that attacks bugs., Diseases [C] - Immune System Diseases [C20]

 

 

Not yet recruiting

2

12

Europe

ALN-CC5, [ALN-62643], Solution for injection

IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI, Alnylam Pharmaceutical Inc. Cambridge, MA, Istituto di Ricerche Farmacologiche Mario negri

Atypical Hemolytic Uremic Syndrome Sindrome emolitico uremica atipica, Atypical Hemolytic Uremic Syndrome Sindrome emolitico uremica atipica, Diseases [C] - Blood and lymphatic diseases [C15]

 

 

Completed

2

6

Europe

Pozelimab, REGN3918, Cemdisiran, ALN-CC5

Regeneron Pharmaceuticals

Paroxysmal Nocturnal Hemoglobinuria

05/22

05/23

Recruiting

2

8

RoW

Eculizumab

Peking University First Hospital

Autoimmune Diseases

08/26

12/26

Not yet recruiting

2

12

NA

NM8074, Soliris, Eculizumab

NovelMed Therapeutics

Paroxysmal Nocturnal Hemoglobinuria

08/26

01/27

Not yet recruiting

1/2

30

RoW

Eculizumab, Soliris

Tao Lin

Kidney Transplantation

07/25

12/25

Recruiting

1

120

RoW

Soliris 300 MG in 30 ML Injection, TUR03 300 MG in 30 ML Injection

Turgut Ardika PTY LTD

Healthy

07/24

10/24

No Longer Available

N/A

Europe, US

eculizumab, Soliris

Alexion Pharmaceuticals

COVID-19, Pneumonia, Viral, Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)

 

 

Completed

N/A

44

RoW

Elizaria®, Eculizumab

AO GENERIUM

Paroxysmal Nocturnal Hemoglobinuria

12/22

05/23

Recruiting

N/A

11

RoW

AstraZeneca

Observational

10/24

10/24

Not yet recruiting

N/A

10

 

Eculizumab

West China Hospitai, Sichuan University; West China Hospitai, Sichuan University, Apply for hospital project funds

paroxysmal nocturnal hemoglobinuria